Www absynth skin#

Improvements in health practices and judicious use of antibiotics have reduced the number of S.aureus infections in the last 10 years, nonetheless the level of S. MRSA infects patients in the hospital and in the community and is responsible for up to 25% of all healthcare-associated infections. Accidents, surgery or device implantation that breach natural barriers, allow invasion, which may result in life-threatening infections such as pneumonia and blood-borne infections particularly by the antibiotic resistant form (MRSA).

Www absynth skin#

aureusis a bacterium that colonises the nasal lining and skin of >30% of people. aureus in a well-recognised model of disease. In its lead programme, the company has shown that its selected protein antigen formulations can protect against infections caused by S. The Absynth team are highly motivated and complemented by industry specific non-executive directors, all of whom work together to combat the very concerning threat of drug resistant bacteria.'Ĭenkos Securities plc +44 (0) 20 7397 8900Įlizabeth Bowman, Bobbie Hilliam (Corporate Finance)Īllerton Communications +44 (0) 20 3137 2500Ībsynth Biologics is a company with an innovative antibacterial platform that has identified novel protein antigens, conserved and essential for the life of bacteria that harness the immune system by a dual-action mechanism to eliminate bacteria: direct antibody-mediated antibacterial activity and engagement of classic immune effector functions. Peter Grant, Operations Director for Fusion IP and Absynth's chairman, said: 'We very much look forward to developing Absynth with our new investor, the North West Fund, to create a very exciting range of products in infectious diseases. We're delighted to make this investment into such a forward thinking company which is clearly passionate about combating infectious diseases.' aureus vaccine and pipeline R&D programmes.'ĭr Penny Attridge, senior investment director at SPARK Impact and manager of The North West Fund for Biomedical, said: 'We hope that this funding will help Absynth Biologics to continue to excel and further develop its products to make a real difference in targeting infectious diseases. This investment will fund exciting stages of development for Absynth's S.

The North West Fund for Biomedical is part of the wider £155m North West Fund, financed jointly by the European Regional Development Fund and the European Investment Bank.įiona Marston, Chief Executive of Absynth Biologics, said: 'I am delighted to have the support of our new investor The North West Fund for Biomedical and the ongoing support of our existing shareholder Fusion IP. Post-funding, Fusion will own a 42.84% equity shareholding in Absynth. The North West Fund for Biomedical, managed by SPARK Impact, is investing £400,000 and Fusion IP is investing £450,000. This brings the total awarded to Absynth since 2012 to £175,000 in two grants from the TSB.

The investment will also complement funding secured from the Biomedical Catalyst - a funding stream administered by the UK's innovation agency, the Technology Strategy Board (TSB), to further develop Absynth's product pipeline. Lead programmes undertaken by Absynth target Staphylococcus aureus including its drug-resistant form MRSA, against which vaccines and antibodies of other companies have failed to show clinical efficacy - Absynth's approach has the potential to succeed where others have previously failed.Ībsynth's novel antigens offer broad potential against a range of bacterial infections and form the basis of the company's pipeline that includes vaccines to prevent Clostridium difficile and Streptococcus pyogenes infections.Ībsynth will use the investment to advance the Staphylococcus aureus programme to key pre-clinical milestones. Bacterial infections are a major cause of death worldwide, with microbial drug resistance being a significant contributing factor. It has developed a distinctive, non-conventional approach to developing vaccines and therapeutic antibodies based on identifying novel, conserved bacterial antigens that are essential and also antibody-accessible. Fusion IP plc (AIM: FIP), the university commercialisation company that turns world-class research into business, is pleased to announce that Absynth Biologics Limited ('Absynth'), one of Fusion's portfolio companies, has secured £850,000 in funding from new and existing investors.Ībsynth is a UK biotechnology spinout company from the University of Sheffield.